High-impact quarter for Neurotech International

Published at Aug 1, 2018, in Biotech

Neurotech International (ASX:NTI), developer of quality medical solutions aimed at improving the lives of children with autism, has released its quarterly activities for the period ending June 30 2018, reporting strong progress.

Following provisional acceptance of the US clinical trial for Mente Autism by leading medical journal, Frontiers in Neurology in June, NTI recently revealed that full results of the trial had been published. Confirming the positive impact of Mente Autism for children with autism spectrum disorder (ASD), these results showed significant changes in the active treatment group, including:

  • Significant reductions in the brain wave frequency bands of interest, delta, beta and high beta, which are typically abnormally high in children with autism
  • Improved balance with eyes open rather than closed, which is the opposite effect experienced by autistic children
  • Positive effects and a reduction of autistic behaviors across questionnaires used globally as validated tools in clinical applications
  • Parents indicating significant improvements in social skills and communication of their children

In June, NTI also announced CE acceptance of considerable improvements to Mente Autism, enabling the company to move ahead with production. These include improvements to wi-fi connectivity, synchronisation and usability linked to the firmware and the Mente Autism application.

As always, it should be noted that NTI is an early stage play and anything can happen, so seek professional financial advice if considering this stock for your portfolio.

A bit more on NTI’s successful US clinical trial

The clinical trial, which was carried out by Florida's Carrick Institute, was a randomised-controlled, double-blind investigation that compared Mente Autism with a control (or sham) device over 12 weeks.

This trial was designed to ascertain the consequences of the Mente Autism neurofeedback treatment, with a variety of outcome measurements examined to assess the effectiveness of the device. This included analysis of brain activity, balance and behavior. Evaluations were completed at enrolment and again after the 12-week therapy concluded.

More than 700 potential subjects aged 5-17 applied to participate in the trial, with 83 recruited and 34 participants completing.

Critically, these positive results suggest that Mente Autism is uniquely positioned to target autism as a home-based neurofeedback tool, and clinical evidence from the trial will be used to support the NTI’s submission to the US Food and Drug Administration (FDA), which is targeted for the third quarter of calendar 2018.

NTI held a webinar to discuss the US clinical trial on 12 July 2018, which is available here

NTI onboards new Non-Executive Director

Following the retirement of Neurotech founder, Dr Adrian Attard Trevisan, as a Non-Executive Director in June, NTI has onboarded neuroscience expert, Dr David Cantor.

Cantor is a highly distinguished clinician, neuroscientist, program developer and a member of the NTI’s scientific advisory board, with a career spanning more than 40 years in the academic and clinical neuroscience sector.

He is CEO and Clinical Director of Mind and Motion Developmental Centers of Georgia, a multidisciplinary treatment facility providing a range of diagnostic and treatment services to children and adults seeking help with neurological disorders such as autism, ADHD, traumatic brain injury, and sensory processing disorders.

On top of that, Cantor is also the CEO and Managing Partner of BrainDx, an international software company that produces functional brain analytic software through computer assisted quantitative EEG (QEEG) reports and big database measures of brain development.

Moving forward

Promisingly, with its positive US clinical trial results now in hand, RGI’s next regulatory milestone will be obtaining the US FDA clearance for the Mente Autism device using a de-novo application process.

NTI expects to complete these elements and provide its submission to the FDA before the end of Q3. Depending on several factors, including the FDA's current backlog, benchmarks indicate the approval would take 9 - 12 months.

Business development & marketing activities a focus for H2 2018

Initial units of the next batch of Mente Autism devices are expected to be available this month, with the first shipment of devices expected in August. Pre-orders have been received from several of NTI’s existing distributors, who are initiating various marketing activities to coincide with the release of the Mente Autism clinical trial results.

Promosalute, Neurotech's Italian distribution partner, has also been active with a series of marketing activities including a targeted online marketing exercise and the opening of the first three neurofeedback centres throughout Italy.

Encouragingly, since the release of the US clinical trial results, NTI has seen a considerable surge in enquiries from potential distributors from other geographies, and management expects to broaden its reach with new distribution agreements through 2018 and 2019, with a focus on establishing a presence in the UK, France and Spain.

S3 Consortium Pty Ltd (CAR No.433913) is a corporate authorised representative of Maven Capital Pty Ltd (AFSL No. 418504). The information contained in this article is general information only. Any advice is general advice only. Neither your personal objectives, financial situation nor needs have been taken into consideration. Accordingly you should consider how appropriate the advice (if any) is to those objectives, financial situation and needs, before acting on the advice.

Conflict of Interest Notice

S3 Consortium Pty Ltd does and seeks to do business with companies featured in its articles. As a result, investors should be aware that the Firm may have a conflict of interest that could affect the objectivity of this article. Investors should consider this article as only a single factor in making any investment decision. The publishers of this article also wish to disclose that they may hold this stock in their portfolios and that any decision to purchase this stock should be done so after the purchaser has made their own inquires as to the validity of any information in this article.

Publishers Notice

The information contained in this article is current at the finalised date. The information contained in this article is based on sources reasonably considered to be reliable by S3 Consortium Pty Ltd, and available in the public domain. No “insider information” is ever sourced, disclosed or used by S3 Consortium.

Facebook
Twitter
LinkedIn